DRG Epidemiology's coverage of non-alcoholic fatty liver disease (NAFLD) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the…
DRG Epidemiology’s coverage of non-alcoholic fatty liver disease (NAFLD) comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of NAFLD for each…
Clarivate Epidemiology's coverage of IBS comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of IBS for each country as well…
Clarivate Epidemiology's coverage of non-alcoholic steatohepatitis (NASH) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the…
Clarivate Epidemiology's coverage of non-alcoholic steatohepatitis (NASH) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the…
Clarivate Epidemiology's coverage of non-alcoholic steatohepatitis (NASH) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the…
Clarivate Epidemiology's coverage of non-alcoholic steatohepatitis (NASH) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the…
Clarivate Epidemiology’s coverage of nonalcoholic steatohepatitis (NASH) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
DRG Epidemiology's coverage of non-alcoholic fatty liver disease (NAFLD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence…
DRG Epidemiology's coverage of non-alcoholic fatty liver disease (NAFLD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence…
DRG Epidemiology's coverage of non-alcoholic fatty liver disease (NAFLD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence…
Cystic fibrosis (CF) is a genetic disease caused by any one of the more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CFTR mutations lead…
Clarivate Epidemiology has created a robust repository of the prevalence of biomarker- and mutation-defined treatment-eligible cancer populations. Using Clarivate’s Biomarker Epidemiology, you…
DRG Epidemiology’s coverage of sickle cell disease (SCD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets in North America and Europe (…
DRG Epidemiology’s coverage of atrial fibrillation comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of atrial fibrillation for…